560 reports of this reaction
2.9% of all ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR reports
#5 most reported adverse reaction
RASH is the #5 most commonly reported adverse reaction for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, manufactured by Vertex Pharmaceuticals Incorporated. There are 560 FDA adverse event reports linking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR to RASH. This represents approximately 2.9% of all 19,269 adverse event reports for this drug.
Patients taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR who experience rash should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RASH is a less commonly reported adverse event for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, but still significant enough to appear in the safety profile.
In addition to rash, the following adverse reactions have been reported for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR:
The following drugs have also been linked to rash in FDA adverse event reports:
RASH has been reported as an adverse event in 560 FDA reports for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
RASH accounts for approximately 2.9% of all adverse event reports for ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, making it a notable side effect.
If you experience rash while taking ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.